Targeted CSF-1R Kinase Inhibitor Expands Non-Surgical Oncology Care
The U.S. Food and Drug Administration granted regulatory approval for pimicotinib on November 10. Marketed under the brand name Pimjetmi by EMD Serono, the once-daily oral kinase inhibitor treats adults with symptomatic tenosynovial giant cell tumor (TGCT). The therapy is approved specifically for patients for whom surgical resection risks worsening functional limitation or severe morbidity. The regulatory determination was finalized by the FDA Oncology Center of Excellence following priority review. Developed originally by Abbisko Therapeutics and licensed globally to Merck KGaA.
Tenosynovial giant cell tumor is a rare, locally aggressive neoplasm arising in the synovial lining of joints, tendon sheaths, and bursae. The disease predominantly impacts working-age adults, inflicting chronic pain and severe joint stiffness across knees and ankles. Repeated surgical interventions frequently lead to permanent disability. Oncology review directors noted in approvals reported by Pharmacy Times and OncLive that pimicotinib provides a once-daily oral treatment option for adult patients living with symptomatic TGCT who face severe functional impairment from repeated surgical resections.
FDA approval was grounded upon positive clinical results from the randomized, double-blind Phase 3 MANEUVER trial. The study enrolled patients with active symptomatic disease who were ineligible for curative joint-preserving surgery. Trial data demonstrated an objective response rate (ORR) of 54% among patients receiving 50 milligrams of daily pimicotinib, compared to 3.2% in the matched placebo cohort. Treated individuals achieved statistically significant gains in active joint range of motion and functional recovery scores. Pimicotinib operates by selectively inhibiting colony-stimulating factor-1 receptor (CSF-1R) kinase activity. By disrupting CSF-1 signaling, the oral molecule systematically depletes tumor-promoting macrophages within the periarticular microenvironment. High receptor selectivity reduced severe hepatotoxicity concerns common in legacy kinase inhibitors.
